

**MERITER IRB #:** 2020-010

**RESEARCH PROTOCOL TITLE:** Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

**PRINCIPAL INVESTIGATOR:** Peter Pryde, MD

**Clinical Trials.Gov Listing at:**

<https://clinicaltrials.gov/ct2/show/NCT04338360?term=convalescent+plasma&draw=3&rank=21>

**STUDY PURPOSE**

The purpose of this study is to determine the effectiveness of Convalescent Plasma in patients with severe or life-threatening COVID-19.

**RESEARCH PROCEDURES**

Patients will receive a one-time infusion of Convalescent Plasma. Medical data will be collected.

**ELIGIBILITY CRITERIA FOR SUBJECTS**

- At least 18 years of age.
- Laboratory confirmed diagnosis of infection with SARS-CoV-2.
- Admitted to an acute care facility for the treatment of Covid-19 complications.
- Severe life threatening COVID-19 Informed consent given by patient or healthcare proxy.

**COMPENSATION/REIMBURSEMENT**

There is no compensation offered for this study

**RESEARCH LOCATION**

Meriter Hospital  
202 S. Park St.  
Madison, WI 53715

**CONTACT PERSON**

Lynn Skatrud or Amanda Gessler

**PHONE:** 608-417-2168

